No Data
No Data
GlucoTrack Advances With Clinical Trials and Funding Boost
Glucotrack | 10-K: Annual report
Express News | Glucotrack 2024 EPS $(68.44) Down From $(34.18) YoY
GlucoTrack Sees Funding Sufficient for 2025 Operating Plan >GCTK
GlucoTrack 2024 Loss/Shr $68.44 >GCTK
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights